JP7540882B2 - 免疫関連細胞の一次繊毛の調整方法および調整剤、並びに、試験試料の評価方法 - Google Patents
免疫関連細胞の一次繊毛の調整方法および調整剤、並びに、試験試料の評価方法 Download PDFInfo
- Publication number
- JP7540882B2 JP7540882B2 JP2019204143A JP2019204143A JP7540882B2 JP 7540882 B2 JP7540882 B2 JP 7540882B2 JP 2019204143 A JP2019204143 A JP 2019204143A JP 2019204143 A JP2019204143 A JP 2019204143A JP 7540882 B2 JP7540882 B2 JP 7540882B2
- Authority
- JP
- Japan
- Prior art keywords
- immune
- primary cilia
- related cells
- cells
- trpm4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004027 cell Anatomy 0.000 title claims description 166
- 210000004081 cilia Anatomy 0.000 title claims description 149
- 238000012360 testing method Methods 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 37
- 239000000126 substance Substances 0.000 claims description 86
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 claims description 47
- 102000003618 TRPM4 Human genes 0.000 claims description 47
- 230000000694 effects Effects 0.000 claims description 30
- 230000019491 signal transduction Effects 0.000 claims description 21
- 210000005175 epidermal keratinocyte Anatomy 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 238000011156 evaluation Methods 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 description 31
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000002609 medium Substances 0.000 description 11
- 230000009870 specific binding Effects 0.000 description 11
- 239000003550 marker Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- DZKIUEHLEXLYKM-UHFFFAOYSA-N 9-phenanthrol Chemical compound C1=CC=C2C(O)=CC3=CC=CC=C3C2=C1 DZKIUEHLEXLYKM-UHFFFAOYSA-N 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 239000000556 agonist Substances 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 102100021596 Interleukin-31 Human genes 0.000 description 4
- 101710181613 Interleukin-31 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- LUFAORPFSVMJIW-ZRJUGLEFSA-N U-73122 Chemical compound N([C@@H]1[C@@]2(C)CC[C@@H]3C4=CC=C(C=C4CC[C@H]3[C@@H]2CC1)OC)CCCCCCN1C(=O)C=CC1=O LUFAORPFSVMJIW-ZRJUGLEFSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- UCEANLBFSXXAJI-UHFFFAOYSA-N 5-butyl-7-chlorobenzo[c]quinolizin-11-ium-6-ol;chloride Chemical compound [Cl-].C1=CC=C2C(CCCC)=C(O)C3=C(Cl)C=CC=C3[N+]2=C1 UCEANLBFSXXAJI-UHFFFAOYSA-N 0.000 description 2
- 108010053423 ADP-ribosylation factor related proteins Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102100023188 Nephrocystin-3 Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SGBVHNKBOCCNHT-UHFFFAOYSA-N 2-(3-amino-6-imino-4,5-disulfoxanthen-9-yl)-5-[5-(2,5-dioxopyrrol-1-yl)pentylcarbamoyl]benzoic acid Chemical compound Nc1ccc2c(-c3ccc(cc3C(O)=O)C(=O)NCCCCCN3C(=O)C=CC3=O)c3ccc(=N)c(c3oc2c1S(O)(=O)=O)S(O)(=O)=O SGBVHNKBOCCNHT-UHFFFAOYSA-N 0.000 description 1
- -1 6-(2-carboxylato-4-carboxyphenyl)-1,2,10,11-tetrahydro-1,2,2,10,10,11-hexamethyl-4,8-bis-(sulfomethyl)-1,11-diaza-13-oxoniapentacene Chemical compound 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101710111924 Nephrocystin-3 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 102100036143 Polycystin-1 Human genes 0.000 description 1
- 101710146367 Polycystin-1 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004117 Somatostatin receptor 3 Human genes 0.000 description 1
- 108090000674 Somatostatin receptor 3 Proteins 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000003627 TRPC1 Human genes 0.000 description 1
- 101150017559 TRPC1 gene Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000003595 dermal dendritic cell Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000031910 intraflagellar transport Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
本発明に係る免疫関連細胞の一次繊毛の調整方法は、免疫関連細胞を、TRPM4のシグナル伝達経路を活性化または不活性化させるシグナル制御物質に接触させる接触工程を有する。
本発明に係る免疫関連細胞の一次繊毛の調整剤は、TRPM4のシグナル伝達経路を活性化または不活性化させるシグナル制御物質を含有する。
本発明に係る試験試料の評価方法は、免疫関連細胞を、TRPM4のシグナル伝達経路を活性化または不活性化させるシグナル制御物質に接触させた後、当該免疫関連細胞の一次繊毛を観察する、第1の観察工程と、
上記免疫関連細胞を、上記第1の観察工程に用いた上記シグナル制御物質、および、試験試料に接触させた後、当該免疫関連細胞の一次繊毛を観察する、第2の観察工程と、
上記第1の観察工程の観察結果と、上記第2の観察工程の観察結果とを比較することによって、上記試験試料が上記免疫関連細胞の一次繊毛に及ぼす影響を評価する評価工程と、を有する。
第1の観察工程では、免疫関連細胞をTRPM4のシグナル伝達経路を活性化または不活性化させるシグナル制御物質に接触させた後、当該免疫関連細胞の一次繊毛を観察する。
[免疫関連細胞の一次繊毛の形成率]=〔[検体に含まれる免疫関連細胞が有する一次繊毛の全数]/[検体に含まれる免疫関連細胞の全数]〕×100 ・・・式(I)。
[免疫関連細胞の一次繊毛の形成率]=〔[検体に含まれる一次繊毛を有する免疫関連細胞の全数]/[検体に含まれる免疫関連細胞の全数]〕×100 ・・・式(II)。
第2の観察工程では、免疫関連細胞を、第1の観察工程に用いたシグナル制御物質、および、試験試料に接触させた後、当該免疫関連細胞の一次繊毛を観察する。
評価工程では、第1の観察工程の観察結果と、第2の観察工程の観察結果とを比較することによって、試験試料が免疫関連細胞の一次繊毛に及ぼす影響を評価する。
HaCat細胞(ヒト表皮角化細胞株)を培養している培地に、(i)IL-4、IL-13、およびTNFαの混合物、または、(ii)IL-4、IL-13、TNFα、およびBTP2の混合物、を加えた。なお、培地中の各サイトカインの濃度と、BTP2の濃度とは、図1に示す濃度に調節した。なお、図1中の「ctrl」は、培地にサイトカイン、およびBTP2を加えていない試験に対応している。培地に上述した(i)または(ii)の混合物を加えた後、当該混合物の存在下にて、HaCat細胞を48時間培養した。
[一次繊毛の形成率]=[画像中の一次繊毛の数]/[画像中の全細胞核数]×100
・・・・・(Ia)。
HaCat細胞(ヒト表皮角化細胞株)を培養している培地に、TRPM4のアンタゴニストである9-phenanthrolを加えた。なお、培地中の各9-phenanthrolの濃度と刺激時間とは、図2に示すように、5μMの濃度にて24hの刺激、5μMの濃度にて48hの刺激、10μMの濃度にて24hの刺激、10μMの濃度にて48hの刺激、に調節した。なお、図2中の「ctrl」は、培地に9-phenanthrolを加えていない試験に対応している。培地に各阻害剤を加えた後、阻害剤存在下にて、HaCat細胞を24時間、または48時間培養した。
初代ヒト表皮角化細胞の培地に、(i)IL-31、(ii)IL-31、およびBTP2の混合物、または、(iii)9-phenanthrol、を加えた。なお、培地中の各物質の濃度は図3に示す濃度に調節した。なお、図3中の「ctrl」は、培地に(i)~(iii)の物質を加えていない試験に対応している。
Claims (3)
- 免疫関連細胞を、TRPM4のシグナル伝達経路を活性化させるシグナル制御物質に接触させて、一次繊毛を減少させる接触工程、または、
免疫関連細胞を、TRPM4のシグナル伝達経路を不活性化させるシグナル制御物質に接触させて、一次繊毛を増加させる接触工程、を有し、
上記免疫関連細胞は、HaCat細胞または表皮角化細胞である、免疫関連細胞の一次繊毛の調整方法。 - TRPM4のシグナル伝達経路を活性化させて一次繊毛を減少させる、またはTRPM4のシグナル伝達経路を不活性化させて一次繊毛を増加させる、シグナル制御物質を含有する、免疫関連細胞の一次繊毛の調整剤であって、
上記免疫関連細胞は、HaCat細胞または表皮角化細胞である、調整剤。 - 免疫関連細胞を、TRPM4のシグナル伝達経路を活性化させて一次繊毛を減少させる、またはTRPM4のシグナル伝達経路を不活性化させて一次繊毛を増加させる、シグナル制御物質に接触させた後、当該免疫関連細胞の一次繊毛を観察する、第1の観察工程と、
前記免疫関連細胞を、前記第1の観察工程に用いた前記シグナル制御物質、および、試験試料に接触させた後、当該免疫関連細胞の一次繊毛を観察する、第2の観察工程と、
前記第1の観察工程の観察結果と、前記第2の観察工程の観察結果とを比較することによって、前記試験試料が前記免疫関連細胞の一次繊毛に及ぼす影響を評価する評価工程と、を有し、
上記免疫関連細胞は、HaCat細胞または表皮角化細胞である、試験試料の評価方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019204143A JP7540882B2 (ja) | 2019-11-11 | 2019-11-11 | 免疫関連細胞の一次繊毛の調整方法および調整剤、並びに、試験試料の評価方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019204143A JP7540882B2 (ja) | 2019-11-11 | 2019-11-11 | 免疫関連細胞の一次繊毛の調整方法および調整剤、並びに、試験試料の評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021073928A JP2021073928A (ja) | 2021-05-20 |
JP7540882B2 true JP7540882B2 (ja) | 2024-08-27 |
Family
ID=75898621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019204143A Active JP7540882B2 (ja) | 2019-11-11 | 2019-11-11 | 免疫関連細胞の一次繊毛の調整方法および調整剤、並びに、試験試料の評価方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7540882B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7280913B2 (ja) | 2021-04-26 | 2023-05-24 | プライムプラネットエナジー&ソリューションズ株式会社 | 非水電解質二次電池および電池モジュール |
WO2023047810A1 (ja) | 2021-09-21 | 2023-03-30 | 株式会社マンダム | 免疫関連細胞の一次繊毛の抑制剤およびその利用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019172419A1 (ja) | 2018-03-09 | 2019-09-12 | 株式会社マンダム | 免疫関連疾患の指標の検出方法 |
WO2019177099A1 (ja) | 2018-03-15 | 2019-09-19 | 株式会社マンダム | 被験試料の評価方法 |
-
2019
- 2019-11-11 JP JP2019204143A patent/JP7540882B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019172419A1 (ja) | 2018-03-09 | 2019-09-12 | 株式会社マンダム | 免疫関連疾患の指標の検出方法 |
WO2019177099A1 (ja) | 2018-03-15 | 2019-09-19 | 株式会社マンダム | 被験試料の評価方法 |
Non-Patent Citations (1)
Title |
---|
Am. J. Physiol. Renal. Physiol.,2015年,Vol.309,pp.F697-F707 |
Also Published As
Publication number | Publication date |
---|---|
JP2021073928A (ja) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Asano et al. | Involvement of αvβ5 integrin in the establishment of autocrine TGF-β signaling in dermal fibroblasts derived from localized scleroderma | |
Song et al. | Substance P induction of murine keratinocyte PAM 212 interleukin 1 production is mediated by the neurokinin 2 receptor (NK‐2R) | |
EP2564202B1 (en) | Methods for detecting anti-drug antibodies | |
TW200823233A (en) | ELISA for VEGF | |
JP7540882B2 (ja) | 免疫関連細胞の一次繊毛の調整方法および調整剤、並びに、試験試料の評価方法 | |
US20230355787A1 (en) | Compositions and methods for predicting response to napi2b-targeted therapy | |
BRPI0609449A2 (pt) | detecção de agentes de modulação de gdf-8 | |
Hornig et al. | Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA | |
US8030454B2 (en) | Anti-hedgehog antibodies | |
MX2007011405A (es) | Deteccion de una respuesta inmune para agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8). | |
JP2022106701A (ja) | 試料における細胞間相互作用を検出するためのキット、方法、およびそれらの使用 | |
CN111527407A (zh) | 免疫相关疾病的指标的检测方法 | |
CN101405408A (zh) | 增强淋巴功能的方法 | |
TWI405966B (zh) | 轉錄調控物組合物 | |
EP3244911B1 (en) | A method for determining a likely effect of a treatment to improve male infertility | |
CN113677994A (zh) | 用于评估t细胞功能和预测对疗法的应答的方法和药剂 | |
JP2021075516A (ja) | 免疫関連細胞の一次繊毛の調整方法および調整剤、試験試料の評価方法、並びに、その利用 | |
Zhang et al. | A novel BCMA immunohistochemistry assay reveals a heterogenous and dynamic BCMA expression profile in multiple myeloma | |
WO2022186041A1 (ja) | キメラFcεRIα鎖遺伝子、キメラFcεRIα鎖タンパク質、細胞、分析用キット、及び分析方法 | |
JP7295683B2 (ja) | 皮膚疾患の指標の検出方法、物質の評価方法、並びに、ロリクリン量及び/又はフィラグリン量の増加剤 | |
EP3362087A1 (en) | BINDING ACTIVITY OF AMINOACYL-tRNA SYNTHETASE IN CHARCOT-MARIE-TOOTH (CMT) NEUROPATHY AND CMT-RELATED NEUROLOGICAL DISEASES | |
JP2008261764A (ja) | キナーゼ阻害物質の測定方法 | |
Song et al. | Proteinase-Activated Receptor 1 Inhibition Alleviates Intestinal Fibrosis in Mice with Chronic Colitis | |
Baldinotti et al. | A nanobody-based proximity ligation assay detects constitutive and stimulus-regulated native Arc/Arg3. 1 oligomers in hippocampal neuronal dendrites | |
JP5954796B2 (ja) | 癌治療剤及び癌の予後判定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221019 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230919 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230926 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240514 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240806 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240815 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7540882 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |